UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 113.219
NA - Nord America 8.865
AS - Asia 4.390
SA - Sud America 811
Continente sconosciuto - Info sul continente non disponibili 577
AF - Africa 133
OC - Oceania 9
Totale 128.004
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 109.826
US - Stati Uniti d'America 8.680
SG - Singapore 1.783
CN - Cina 1.320
NL - Olanda 1.119
BR - Brasile 649
SE - Svezia 573
VN - Vietnam 461
UA - Ucraina 451
DE - Germania 316
FI - Finlandia 267
GB - Regno Unito 201
FR - Francia 184
HK - Hong Kong 135
IN - India 118
BD - Bangladesh 117
CA - Canada 97
IQ - Iraq 60
PK - Pakistan 50
TR - Turchia 50
AR - Argentina 49
RU - Federazione Russa 46
KR - Corea 43
AT - Austria 41
ES - Italia 41
MX - Messico 39
ZA - Sudafrica 37
ID - Indonesia 33
CO - Colombia 28
EC - Ecuador 28
IR - Iran 26
MA - Marocco 25
JP - Giappone 24
BE - Belgio 23
MY - Malesia 19
PL - Polonia 18
TH - Thailandia 18
UZ - Uzbekistan 18
EG - Egitto 17
VE - Venezuela 16
AE - Emirati Arabi Uniti 15
JM - Giamaica 14
LT - Lituania 13
SA - Arabia Saudita 13
CL - Cile 12
JO - Giordania 12
RO - Romania 12
BG - Bulgaria 11
KE - Kenya 11
PE - Perù 11
TN - Tunisia 11
CH - Svizzera 10
IL - Israele 10
PH - Filippine 10
SI - Slovenia 10
CR - Costa Rica 8
DZ - Algeria 8
GR - Grecia 8
PT - Portogallo 8
PY - Paraguay 8
NP - Nepal 7
AU - Australia 6
HN - Honduras 6
IE - Irlanda 6
KZ - Kazakistan 6
OM - Oman 6
PS - Palestinian Territory 6
TW - Taiwan 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
GT - Guatemala 5
HU - Ungheria 5
LB - Libano 5
AL - Albania 4
AZ - Azerbaigian 4
CI - Costa d'Avorio 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
UY - Uruguay 4
AO - Angola 3
CG - Congo 3
CY - Cipro 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SV - El Salvador 3
BH - Bahrain 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MT - Malta 2
NG - Nigeria 2
PA - Panama 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
Totale 127.409
Salva come PNG Salva come JPEG
Città #
Cagliari 105.435
Uta 2.942
Amsterdam 1.087
Singapore 942
Ashburn 721
Woodbridge 680
Fairfield 635
Chandler 526
San Jose 523
Dallas 407
Houston 372
Boardman 370
Nyköping 352
Ann Arbor 293
Beijing 284
Wilmington 270
Council Bluffs 243
Seattle 220
Cambridge 210
Los Angeles 190
Jacksonville 189
Dearborn 178
Helsinki 174
Santa Clara 155
Chicago 141
Milan 139
Ho Chi Minh City 133
Rome 121
Hong Kong 118
Lauterbourg 114
The Dalles 113
Boston 111
Shanghai 104
Buffalo 101
Nanjing 89
Hanoi 83
Hefei 82
New York 82
Dong Ket 64
San Diego 56
Salt Lake City 52
São Paulo 48
Naples 46
Guangzhou 45
Redondo Beach 42
Nuremberg 38
Seoul 38
Columbus 33
Toronto 32
Brooklyn 30
Munich 30
Tampa 30
Phoenix 29
Frankfurt am Main 28
Hebei 27
London 27
Orem 27
Redwood City 27
Sassari 26
Montreal 25
Shenyang 24
Elk Grove Village 23
Bari 22
Brussels 22
Da Nang 22
Johannesburg 22
Tianjin 22
Tokyo 22
Turin 22
Baghdad 21
Changsha 21
Rio de Janeiro 20
Vienna 20
Florence 19
Nanchang 19
Salvador 19
Curitiba 18
Denver 18
Jiaxing 18
Chennai 17
Jinan 17
Mountain View 17
Bologna 16
Verona 16
Atlanta 15
Lappeenranta 15
Manchester 15
San Francisco 15
Tashkent 15
Warsaw 15
Livorno 14
Newark 14
Catania 13
Haiphong 13
Mexico City 13
Seregno 13
Washington 13
Zhengzhou 13
Ankara 12
Dhaka 12
Totale 120.426
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 4.111
Current growth patterns in children and adolescents with thalassemia major 3.016
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.933
A genetic score for the prediction of beta-thalassemia severity 2.928
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.718
Deferasirox and children: From clinical trials to the real world 2.497
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.367
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.280
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.182
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.160
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 2.097
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 2.041
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 2.034
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 2.002
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.987
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.927
Investigating the Alpha 1Ncol mutation 1.882
Hematological phenotypes in children according to the α-globin genotypes 1.793
null 1.759
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.725
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.660
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.537
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.537
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.486
Deferasirox: pharmacokinetics and clinical experience 1.461
β-Thalassemia 1.441
Alpha-Thalassemia 1.361
A complicated disease: What can be done to manage thalassemia major more effectively? 1.338
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.327
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.324
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.287
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.273
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.196
Prospettive in Pediatria 1.188
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.181
Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice. 1.175
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.163
Combined therapy with deferiprone and desferrioxamine in thalassemia major 1.093
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 1.064
Lack of heart iron overload in patients with thalassemia intermedia. 1.025
Onset of cardiac iron loading in pediatric patients 1.020
null 1.009
Urinary hepcidin in thalassemic syndromes 909
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 897
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 896
null 886
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 873
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 846
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 844
Pregnancy in Thalassemia 821
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 793
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 774
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 769
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 767
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 755
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 740
Beta-thalassemia 736
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 734
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 731
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 716
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 709
Genetic basis, pathophysiology and diagnosis 702
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 701
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 701
Changing patterns of thalassaemia in Italy: a WebThal perspective. 693
Retrospective evaluation of different iron chelators on cardiac T2* 689
Pathophysiology of beta thalassaemia 683
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 682
Pregnancy and β-thalassemia: An Italian multicenter experience 673
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 673
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 666
Beta-Thalassemia. 658
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 650
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 645
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 619
null 618
Cholelithiasis in thalassemia major 617
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 614
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 606
Phenoconversion’ in adult patients with β-thalassemia 589
null 589
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 588
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 579
Neutropenia in patients with thalassemia major. 577
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 574
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies" 570
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 568
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 561
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 556
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 542
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 540
null 539
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 534
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload 533
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 524
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 523
Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending 508
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 505
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) 500
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 499
Totale 113.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.575
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.575
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227.435 0 540 416 589 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202524.749 4.381 4.815 4.101 3.125 1.580 1.876 1.983 153 416 1.342 692 285
2025/20267.995 714 343 908 696 581 833 1.081 507 676 814 497 345
2026/2027593 224 369 0 0 0 0 0 0 0 0 0 0
Totale 128.004